OMEROS CORP Current Assets
OMEROS CORP (OMER) had Current Assets of $185.24 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-12
- 2026-06-30: Assets, Current $185.24M.
- 2026-03-31: Assets, Current $180.35M.
- 2025-12-31: Assets, Current $215.67M.
- 2025-09-30: Assets, Current $71.81M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $185.24M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $180.35M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $215.67M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $71.81M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $69.65M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $96.18M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $134.12M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $164.92M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $202.93M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $280.96M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $217.90M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $351.34M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $388.56M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $417.04M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $443.24M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $288.55M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $192.72M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $210.22M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $247.96M 10-K · filed 2023-03-13 | $247.89M 10-K · filed 2022-03-01 |
| 2021-09-30 | $91.35M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $112.40M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $132.48M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $151.28M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $195.99M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $38.93M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $85.61M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $103.75M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $63.80M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $65.94M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $76.87M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $89.87M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $66.00M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $96.50M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $78.68M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $108.37M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $117.90M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $53.09M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $51.35M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $60.26M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $60.65M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $34.10M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $24.32M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $37.15M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $39.46M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $56.68M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $73.07M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $9.04M 10-K · filed 2016-03-15 | $9.16M 10-K · filed 2015-03-16 |
| 2014-09-30 | $23.36M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $38.97M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $54.13M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $14.82M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $10.27M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $21.27M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $15.81M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $24.70M 10-K · filed 2014-03-13 | |
| 2012-09-30 | $31.44M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $8.52M 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $19.70M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $25.95M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $33.84M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $39.67M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $43.75M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |